相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: Delineation of anti-leukemic mechanisms of action
Elodie Lainey et al.
BIOCHEMICAL PHARMACOLOGY (2011)
p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12
Kensuke Kojima et al.
BLOOD (2011)
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Takashi Sato et al.
BLOOD (2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
Prognostic Value of FLT3 Mutations Among Different Cytogenetic Subgroups in Acute Myeloid Leukemia
Fabio P. S. Santos et al.
CANCER (2011)
Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
Amanda Parmar et al.
CANCER RESEARCH (2011)
JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia
Fatih M. Uckun et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Therapeutic Advances in Acute Myeloid Leukemia
Alan Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
Keith W. Pratz et al.
BLOOD (2010)
FLT3 as a therapeutic target in AML: still challenging after all these years
Thomas Kindler et al.
BLOOD (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: A case report
J. Winkler et al.
LEUKEMIA RESEARCH (2010)
FLT3/internal tandem duplication subclones in acute myeloid leukemia differ in their engraftment potential in NOD/SCID mice
Alice M. S. Cheung et al.
LEUKEMIA RESEARCH (2010)
The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells
Chunling Wang et al.
LEUKEMIA RESEARCH (2010)
New Trends in the Standard of Care for Initial Therapy of Acute Myeloid Leukemia
Hugo F. Fernandez
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation
Goichi Yoshimoto et al.
BLOOD (2009)
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Stephan Metzelder et al.
BLOOD (2009)
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation
Yukimasa Shiotsu et al.
BLOOD (2009)
Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia
Soheil Meshinchi et al.
CLINICAL CANCER RESEARCH (2009)
JAK3: A two-faced player in hematological disorders
Melanie G. Cornejo et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Structural and numerical variation of FLT3/ITD in pediatric AML
Soheil Meshinchi et al.
BLOOD (2008)
Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model
Li Li et al.
BLOOD (2008)
Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo
Chie Nishioka et al.
BLOOD (2008)
A human breast cell model of preinvasive to invasive transition
Aylin Rizki et al.
CANCER RESEARCH (2008)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Rosemary E. Gale et al.
BLOOD (2008)
The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2
William G. Stetler-Stevenson
CANCER AND METASTASIS REVIEWS (2008)
Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential
A. M. S. Cheung et al.
LEUKEMIA (2007)
Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells
Kyu-Tae Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412
C. H. Seedhouse et al.
LEUKEMIA (2006)
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J. DeAngelo et al.
BLOOD (2006)
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD
Jennifer L. Rocnik et al.
BLOOD (2006)
Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
HS Radomska et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML
DJ Pearce et al.
BLOOD (2006)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
F Heidel et al.
BLOOD (2006)
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myelold transformation
CH Brandts et al.
CANCER RESEARCH (2005)
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells
M Levis et al.
BLOOD (2005)
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations
C Choudhary et al.
BLOOD (2005)
Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
ACP Riddick et al.
BRITISH JOURNAL OF CANCER (2005)
Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia
S Scholl et al.
JOURNAL OF LABORATORY AND CLINICAL MEDICINE (2005)
Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples
DJ Pearce et al.
STEM CELLS (2005)
FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)
K Bagrintseva et al.
BLOOD (2005)
RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation
J Schwäble et al.
BLOOD (2005)
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)
T Kindler et al.
BLOOD (2005)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML
JR Jiang et al.
BLOOD (2004)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
W Fiedler et al.
BLOOD (2003)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia:: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
LY Shih et al.
BLOOD (2002)
Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy
N Boissel et al.
LEUKEMIA (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
S Meshinchi et al.
BLOOD (2001)
分享论文
